Literature DB >> 6872291

Propranolol in pregnancy three year prospective study.

I Livingstone, P W Craswell, E B Bevan, M T Smith, M J Eadie.   

Abstract

We compared propranolol with methyldopa in a randomized prospective study of 28 women with pregnancy associated hypertension. Both drugs were equally effective in controlling maternal hypertension. There was no significant difference in the birthweights of the babies in each group. However one infant born to a mother receiving propranolol had symptomatic hypoglycaemia. The mean peak levels of propranolol, propranolol glucuronide, 4-hydroxypropranolol, and 4-hydroxypropranolol glucuronide were not significantly different in the first, second, third trimesters and at least 3 months post partum. The mean peak plasma level of naphthoxylactic acid however was significantly less in the third trimester compared with post partum levels. Propranolol and its metabolites were found to cross into breast milk with the maximum dose likely to be ingested by the infant as either propranolol or propranolol glucuronide being 7 micrograms of propranolol per 100 g of breast milk, being approximately 0.1% of the maternal dose.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872291     DOI: 10.3109/10641958309006092

Source DB:  PubMed          Journal:  Clin Exp Hypertens B        ISSN: 0730-0085


  9 in total

1.  Treatment of cardiovascular diseases.

Authors:  K R Lees; P C Rubin
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-07

2.  Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.

Authors:  M T Smith; I Livingstone; M J Eadie; W D Hooper; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

Authors:  E Rey; J LeLorier; E Burgess; I R Lange; L Leduc
Journal:  CMAJ       Date:  1997-11-01       Impact factor: 8.262

4.  Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy.

Authors:  M J Boutroy; P L Morselli; G Bianchetti; J L Boutroy; L Pépin; A Zipfel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Placental transfer and perinatal pharmacokinetics of betaxolol.

Authors:  P L Morselli; M J Boutroy; G Bianchetti; A Zipfel; J L Boutroy; P Vert
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.

Authors:  Jeffrey N Bone; Akshdeep Sandhu; Edgardo D Abalos; Asma Khalil; Joel Singer; Sarina Prasad; Shazmeen Omar; Marianne Vidler; Peter von Dadelszen; Laura A Magee
Journal:  Hypertension       Date:  2022-01-04       Impact factor: 9.897

Review 7.  The Risk for Neonatal Hypoglycemia and Bradycardia after Beta-Blocker Use during Pregnancy or Lactation: A Systematic Review and Meta-Analysis.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Viraraghavan V Ramaswamy; Sinno H P Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  Int J Environ Res Public Health       Date:  2022-08-04       Impact factor: 4.614

8.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Authors:  Edgardo Abalos; Lelia Duley; D Wilhelm Steyn; Celina Gialdini
Journal:  Cochrane Database Syst Rev       Date:  2018-10-01

Review 9.  Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Louise M Webster; Frances Conti-Ramsden; Paul T Seed; Andrew J Webb; Catherine Nelson-Piercy; Lucy C Chappell
Journal:  J Am Heart Assoc       Date:  2017-05-17       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.